Clinical Trials Directory

Trials / Completed

CompletedNCT02214862

2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism

Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Fundacion Clinic per a la Recerca Biomédica · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The PET tracer \[F18\]-FDDNP has a specific affinity for lesions containing tau protein. The study consists of two phases: * In the first (cross-sectional) phase it will be assessed the uptake of \[18F\]-FDDNP in 10 cases with progressive supranuclear palsy (PSP, a tauopathy) en 10 with multi-system atrophy (MSA, a non-tauopathy), along with 20 individuals with Unclassifiable Parkinsonism, as previously defined in a European cohort study. * In the second (longitudinal) phase it will be prospectively followed the 20 unclassifiable patients (at 6, 12 and 18 months) by means of validated scales and accepted diagnostic criteria in order to try to correlate their eventual clinical diagnosis with baseline PET findings. On this basis, we endeavour to estimate the ability of this technique to detect in vivo underlying tau pathology in subjects initially unclassifiable on clinical grounds. We hypothesized that: 1. Patients with clinically definite PSP will present an increased uptake in basal ganglia, brainstem and cerebellum. 2. Patients with clinically defined MSA will not present specific uptake. 3. Part of unclassifiable patients with parkinsonism will present a pattern of uptake similar to patients with clinically defined PSP and this part along the clinical follow-up will be meet clinical criteria for diagnose of PSP

Conditions

Interventions

TypeNameDescription
DRUG[F18]-FDDNPradiopharmaceutical tracer

Timeline

Start date
2013-03-01
Primary completion
2015-12-01
Completion
2016-02-01
First posted
2014-08-12
Last updated
2016-02-04

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02214862. Inclusion in this directory is not an endorsement.